胰臟外分泌功能不全 (EPI) 治療市場：按疾病管理、藥物、最終用戶和地區分類。

預計到 2026 年，外分泌胰臟功能不全 (EPI) 治療市場規模將達到 25.5 億美元，到 2033 年將達到 33.7 億美元。預計 2026 年至 2033 年的複合年成長率將達到 4.1%。

這個市場正經歷穩定成長，主要受以下因素驅動：慢性胰臟炎和其他胰臟疾病的盛行率上升、EPI 的診斷和治療不斷增加、胰酶替代療法 (PERT) 的廣泛採用，以及人們對與 EPI 相關的吸收不良和營養缺乏的認知不斷提高。

外分泌性胰臟功能不全的特徵是胰臟消化酵素的產生或分泌不足，導致消化和營養吸收障礙。這種情況通常與慢性胰臟炎、囊腫纖維化、胰臟癌、急性胰臟炎、胰臟手術以及其他胃腸道和胰臟疾病有關。治療主要包括胰酵素替代療法（PERT），通常合併營養管理和飲食療法，以改善消化、營養吸收和營養狀況。

為了改善外分泌性胰臟炎（EPI）患者的預後，醫療專業人員越來越重視早期診斷、酵素劑量最佳化、營養監測和治療順從性。臨床管理的進步也使得基於食物攝取量、脂肪攝取量、疾病嚴重程度、症狀和營養反應等因素的個人化胰酶替代療法（PERT）劑量設定更加合理。此外，新一代重組口服胰酶替代療法的研發有望拓展未來的治療選擇，並可能緩解傳統豬源性胰酶製劑的限制。

市場動態

由於慢性胰臟炎、囊腫纖維化、胰臟癌以及其他與外分泌胰臟功能障礙相關的疾病負擔日益加重，市場呈現穩定成長動能。隨著確診患者數量的增加，對長期胰酶替代療法的需求也日益成長，尤其是在那些出現消化不良、吸收不良、體重下降和營養缺乏等症狀的患者中。

臨床對胰酶替代療法 (PERT) 的認知和應用不斷提高是市場成長的關鍵促進因素。 PERT 仍然是腎積水 (EPI) 的主要治療方法，廣泛用於恢復消化酶活性和改善營養吸收。醫師對該療法的認知不斷提高、臨床指南不斷完善以及對適當酵素劑量重要性的日益重視，都進一步促進了該療法的應用。

此外，胃腸病學基礎設施的進步和處方酶療法的可及性提高也對市場產生了積極影響。製藥公司、胃腸病學家、胰腺病學家、營養師、醫院藥劑師和專科藥房在支持外分泌胰腺功能不全的診斷、啟動、劑量最佳化和長期管理方面發揮著至關重要的作用。

另一方面，漏診、延誤診斷以及長期胰酶替代療法的高成本仍然是重大挑戰。然而，疾病認知度的提高、治療途徑的擴大、患者支持工作的加強以及新一代重組酶療法的研發，預計將在預測期內推動市場成長。

本次調查的主要特點

• 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究根據以下參數分析了外分泌胰腺功能不全 (EPI) 治療市場的主要參與者：公司概況、產品系列、主要亮點、財務表現和策略。
• 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
• 這份「外分泌胰臟功能不全（EPI）治療市場」報告的目標受群眾外包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等產業相關人員。
• 相關人員可以透過利用分析外分泌胰臟功能不全 (EPI) 治療市場中使用的各種策略矩陣來簡化決策過程。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場概覽

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因子
  • 市場機遇
• 影響分析
• 市場趨勢
• 主要進展
• 產品核准
• 合作關係、併購
• 監理情勢
• PEST分析
• 波特五力分析
• 流行病學
• 穩健的管道分析

第4章 全球外分泌胰臟功能不全（EPI）治療市場：依疾病管理分類，2021-2033年

• 營養管理
• 胰酵素替代療法（PERT）

第5章 全球外分泌胰臟功能不全（EPI）治療市場：依治療藥物分類，2021-2033年

• 克瑞翁
• Zenpep
• 龐克之子
• Ultresa
• Viokace
• 其他

第6章 全球外分泌胰臟功能不全（EPI）治療市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲國家
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第7章 競爭情勢

• 熱圖分析
• 市佔率分析
• 公司簡介
  • AbbVie, Inc.
  • Digestive Care, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Anthera Pharmaceuticals, Inc.
  • Allergan plc
  • AzurRx BioPharma, Inc.
• 分析師意見

第8章

• 參考
• 調查方法
• 關於本公司

Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market is estimated to be valued at USD 2.55 Bn in 2026 and is expected to reach USD 3.37 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.1% from 2026 to 2033.

The market is witnessing steady growth mainly driven by the rising prevalence of chronic pancreatitis and other pancreatic disorders, increasing diagnosis and treatment of EPI, growing adoption of pancreatic enzyme replacement therapy (PERT), and rising awareness regarding EPI-associated malabsorption and nutritional deficiencies.

Exocrine pancreatic insufficiency is characterized by inadequate production or delivery of pancreatic digestive enzymes, resulting in impaired digestion and nutrient absorption. The condition is commonly associated with chronic pancreatitis, cystic fibrosis, pancreatic cancer, acute pancreatitis, pancreatic surgery, and other gastrointestinal or pancreatic disorders. Treatment primarily involves pancreatic enzyme replacement therapy, supported by nutritional management and dietary modification to improve digestion, nutrient absorption, and nutritional status.

Healthcare providers are increasingly focusing on early diagnosis, optimized enzyme dosing, nutritional monitoring, and treatment adherence to improve outcomes among patients with EPI. Advances in clinical management are also encouraging more personalized PERT dosing based on meal size, fat intake, disease severity, symptoms, and nutritional response. In addition, the development of next-generation recombinant oral enzyme replacement therapies is expected to expand future treatment options and potentially reduce limitations associated with conventional porcine-derived pancreatic enzyme products.

Market Dynamics

The market is witnessing steady momentum owing to the rising burden of chronic pancreatitis, cystic fibrosis, pancreatic cancer, and other conditions associated with pancreatic exocrine dysfunction. The growing diagnosed patient population is increasing the requirement for long-term pancreatic enzyme supplementation, particularly among patients experiencing maldigestion, malabsorption, weight loss, and nutritional deficiencies.

Increasing clinical recognition and adoption of pancreatic enzyme replacement therapy is a major factor supporting market growth. PERT remains the principal therapeutic approach for EPI and is widely used to restore digestive enzyme activity and improve nutrient absorption. Increasing physician awareness, improved clinical guidelines, and greater emphasis on appropriate enzyme dosing are further strengthening treatment utilization.

The market is also benefiting from improvements in gastroenterology infrastructure and increasing access to prescription enzyme therapies. Pharmaceutical companies, gastroenterologists, pancreatologists, nutrition specialists, hospital pharmacists, and specialty pharmacies play an important role in supporting diagnosis, treatment initiation, dosing optimization, and long-term management of EPI.

At the same time, underdiagnosis, delayed diagnosis, and the high cost of long-term pancreatic enzyme replacement therapy remain key challenges. However, improving disease awareness, expanding treatment access, patient-support initiatives, and development of next-generation recombinant enzyme therapies are expected to support market expansion during the forecast period.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AbbVie, Inc., Digestive Care, Inc., Janssen Pharmaceuticals, Inc., Anthera Pharmaceuticals, Inc., Allergan plc, AzurRx BioPharma, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market

Market Segmentation

• By Disease Management (Revenue, USD Bn, 2021-2033)
  • Nutritional Management
  • Pancreatic Enzyme Replacement Therapy (PERT)
• By Therapeutic Drugs (Revenue, USD Bn, 2021-2033)
  • Creon
  • Zenpep
  • Pancreaze
  • Ultresa
  • Viokace
  • Others
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa
• Key Players
  • AbbVie, Inc.
  • Digestive Care, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Anthera Pharmaceuticals, Inc.
  • Allergan plc
  • AzurRx BioPharma, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Disease Management
  • Market Snapshot, By Therapeutic Drugs
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Product Approval
• Collaboration/Merge/Acquisition
• Regulatory Landscape
• PEST Analysis
• Porter's Five Forces Analysis
• Epidemiology
• Robust Pipeline Analysis

4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market, By Disease Management, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Nutritional Management
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Pancreatic Enzyme Replacement Therapy (PERT)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market, By Therapeutic Drugs, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Creon
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Zenpep
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Pancreaze
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Ultresa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Viokace
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market, By Region, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Management, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Drugs, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Management, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Drugs, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Management, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Drugs, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Management, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Drugs, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Management, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Drugs, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Management, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Drugs, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
• Company Profile
  • AbbVie, Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Digestive Care, Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Janssen Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Anthera Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Allergan plc
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • AzurRx BioPharma, Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
• Analyst Views

8. Section

• References
• Research Methodology
• About Us